Discontinuation of antipsychotic medication in pregnancy: A cohort study

Schizophrenia Research

Volumn 159, Issue 1, 2014, Pages 218-225

  Petersen, Irene ^a   McCrea, Rachel L ^a   Osborn, David J P ^b   Evans, Stephen ^c   Pinfold, Vanessa ^d   Cowen, Phil J ^e   Gilbert, Ruth ^f   Nazareth, Irwin ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d Faculty of ArtsThe McPin Foundation   (United Kingdom)

^e WARNEFORD HOSPITAL   (United Kingdom)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antipsychotics; Medicine discontinuation; Pregnancy; The health improvement network

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; MAJOR CLINICAL STUDY; MATERNAL AGE; MENTAL DISEASE; PREGNANCY; PRESCRIPTION; PREVALENCE; RELAPSE; RISK ASSESSMENT; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY; TREATMENT DURATION; TREATMENT WITHDRAWAL; UNITED KINGDOM; AGE DISTRIBUTION; CHEMICALLY INDUCED; COHORT ANALYSIS; DRUG UTILIZATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; KAPLAN MEIER METHOD; PREGNANCY COMPLICATIONS; RECEIVER OPERATING CHARACTERISTIC; SCHIZOPHRENIA; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADULT; AGE DISTRIBUTION; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; DRUG UTILIZATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; PREGNANCY; PREGNANCY COMPLICATIONS; ROC CURVE; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84907980097     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.07.034     Document Type: Article

References (23)

1. Blak B.T., Thompson M., Dattani H., Bourke A. Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform. Prim. Care 2011, 19(4):251-255.
2. Chisholm J. The Read clinical classification. Br. Med. J. 1990, 300(6732):1092. (Apr 28).
3. Einarson A., Boskovic R. Use and safety of antipsychotic drugs during pregnancy. J. Psychiatr. Pract. 2009, 15(3):183-192. (May).
4. Epstein R.A., Bobo W.V., Shelton R.C., Arbogast P.G., Morrow J.A., Wang W., et al. Increasing use of atypical antipsychotics and anticonvulsants during pregnancy. Pharmacoepidemiol. Drug Saf. 2013, 22(7):794-801. (Jul).
5. Galbally M., Snellen M., Lewis A.J. A review of the use of psychotropic medication in pregnancy. Curr. Opin. Obstet. Gynecol. 2011, 23(6):408-414. (Dec).
6. Gibson J. Enhanced Dosage Determinations 2012, CSD Medical Research UK.
7. Hardoon S., Hayes J.F., Blackburn R., Petersen I., Walters K., Nazareth I., et al. Recording of severe mental illness in United Kingdom primary care, 2000-2010. PLoS ONE 2013, 8(12):e82365. (Dec 12).
8. Hayes J., Prah P., Nazareth I., King M., Walters K., Petersen I., et al. Prescribing trends in bipolar disorder: cohort study in the United Kingdom THIN primary care database 1995-2009. PLoS ONE 2011, 6(12):e28725. (Dec 7).
9. Howard L.M., Goss C., Leese M., Appleby L., Thornicroft G. The psychosocial outcome of pregnancy in women with psychotic disorders. Schizophr. Res. 2004, 71(1):49-60. (Nov 1).
10. Jones I. Bipolar disorder and childbirth: the importance of recognising risk. Br. J. Psychiatry 2005, 186(6):453-454. (Jun 1).
11. Lis Y., Mann R.D. The VAMP research multi-purpose database in the UK. J. Clin. Epidemiol. 1995, 48(3):431-443. (Mar).
12. Man S.-L., Petersen I., Thompson M., Nazareth I. Antiepileptic drugs during pregnancy in primary care: a UK population based study. PLoS ONE 2012, 7(12):e52339. (Dec 18).
13. National Institute for Health and Clinical Excellence Bipolar disorder: the management of bipolar disorder in adults, children and adolescents, in primary and secondary care [Internet] Available from:. http://www.nice.org.uk/CG38.
14. National Institute for Health and Clinical Excellence Antenatal and postnatal mental health: clinical management and service guidance [Internet] Available from:. http://www.nice.org.uk/CG45.
15. Petersen I., Gilbert R.E., Evans S.J.W., Man S.-L., Nazareth I. Pregnancy as a major determinant for discontinuation of antidepressants. J. Clin. Psychiatry 2011, 72(07):979-985. (Jul 15).
16. Prah P., Petersen I., Nazareth I., Walters K., Osborn D. National changes in oral antipsychotic treatment for people with schizophrenia in primary care between 1998 and 2007 in the United Kingdom. Pharmacoepidemiol. Drug Saf. 2012, 21(2):161-169.
17. Reis M., Källén B. Maternal use of antipsychotics in early pregnancy and delivery outcome. J. Clin. Psychopharmacol. 2008, 28(3):279-288. (Jun).
18. Sadowski A., Todorow M., Yazdani Brojeni P., Koren G., Nulman I. Pregnancy outcomes following maternal exposure to second-generation antipsychotics given with other psychotropic drugs: a cohort study. BMJ Open 2013, 3(7).
19. Toh S., Li Q., Cheetham T.C., Cooper W.O., Davis R.L., Dublin S., et al. Prevalence and trends in the use of antipsychotic medications during pregnancy in the U.S., 2001-2007: a population-based study of 585,615 deliveries. Arch. Womens Ment. Health 2013, 16(2):149-157. (Apr 1).
20. Viguera A.C., Tondo L., Koukopoulos A.E., Reginaldi D., Lepri B., Baldessarini R.J. Episodes of mood disorders in 2,252 pregnancies and postpartum periods. Am. J. Psychiatry 2011, 168(11):1179-1185. (Nov 1).
21. Webb R.T., Howard L., Abel K.M. Antipsychotic drugs for non-affective psychosis during pregnancy and postpartum. Cochrane Database Syst. Rev. 2004, 2:CD00441.
22. WHO Collaborating Centre for Drug Statistics Methodology WHOCC-ATC/DDD Index [Internet] [cited 2013 Dec 2]. Available from:. http://www.whocc.no/atc_ddd_index/.
23. Yonkers K.A., Wisner K.L., Stowe Z., Leibenluft E., Cohen L., Miller L., et al. Management of bipolar disorder during pregnancy and the postpartum period. Am. J. Psychiatry 2004, 161(4):608-620. (Apr).